Navigation Links
Ikaria® To Present at 2011 BIO Business Forum and International Convention
Date:6/21/2011

HAMPTON, N.J., June 21, 2011 /PRNewswire/ -- Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients in the hospital and ICU settings, today announced that its Chairman and CEO, Daniel Tasse, will present at the 2011 Biotechnology Industry Organization (BIO) Business Forum and International Convention on Tuesday, June 28, 2011 from 2:30 to 2:45 p.m. EDT in the Georgetown Room at the Walter E. Washington Convention Center in Washington, DC.

About Ikaria, Inc.Ikaria, Inc. is a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients in the hospital and ICU settings.  Ikaria's therapies are designed to meet the unique and complex medical needs of these critically ill patients. The Company's lead product is INOMAX® (nitric oxide) for inhalation, the only FDA-approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants. It is offered through the INOMAX therapy package, an all-inclusive offering of drug product, drug-delivery system, on-site training and 24/7/365 technical assistance and support. Ikaria, alone or through partners, also markets the INOMAX therapy package in Puerto Rico, Canada, Australia, Mexico and Japan. The Company is pursuing a number of new indications for INOMAX. Ikaria's late-stage pipeline also is comprised of LUCASSIN® (terlipressin), a potential treatment for hepatorenal syndrome Type 1, as well as IK-5001, a potential treatment for preventing cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction. The Company also has a number of investigational compounds in development. Ikaria is headquartered in Hampton, NJ, with research facilities in Seattle, WA and Madison, WI, and manufacturing facilities in Po
'/>"/>

SOURCE Ikaria, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. InterMune to Present at Canaccord Adams Conference
2. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
3. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
4. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CANACCORD ADAMS 28TH ANNUAL GLOBAL GROWTH CONFERENCE
5. Bionovo to Present at Canaccord Adams Global Growth Conference
6. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
7. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
9. Bluestar Silicones Presents Adhesive Gels for Wound Care at Medical Grade Polymers Conference
10. Duska Therapeutics to Present at Noble Financial Equity M.A.D. MAX Conference on Tuesday, August 19th at 1:30 p.m. PDT
11. Cepheid to Webcast Upcoming Financial Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , the leading life sciences employment and news website, launched the ... Illinois , Indiana , ... , Minnesota , Missouri , ... Wisconsin . BioMidwest is a leader in biotech and ... in this region in 2013. The life sciences sector in this area ...
(Date:7/31/2014)... people over 60 are not donor candidates for bone ... time, making the elderly prone to life-threatening infection and ... now has discovered a reason why. , "We have ... blood-forming cells to maintain blood production over time in ... could be restored for rejuvenation therapies," said Emmanuelle Passegu, ...
(Date:7/31/2014)... to see through organs and even the entire body ... fine-grained cellular structures has been a long-time dream of ... July 31st in the journal Cell has ... for making opaque organs, bodies, and human tissue biopsies ... The protocols could pave the way for a better ...
(Date:7/31/2014)... BLOOMINGTON, Ind. -- Chemists at Indiana University Bloomington ... in bricks-and-mortar fashion, a development with potential value ... as field-effect transistors and photovoltaic cells. , Their ... 3D Crystalline Solids and 2D Self-Assembled Crystals," has ... a journal of the Royal Society of Chemistry. ...
Breaking Biology Technology:Midwest Biotech Leaders Featured On BioSpace Map 2Key to aging immune system is discovered 2See-through organs and bodies will accelerate biomedical discoveries 2Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 2Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 3
... , 3Q09 Corporate Highlights: , ... Europe Ltd. Made significant progress in commercial readiness ... Director, Marketing; and Director, Commercial Operations Appointed Bradford S. ... , Upcoming 2009 Milestones: , ...
... Nov. 6 Intarcia Therapeutics, Inc. delivered two presentations ... exenatide) program for the treatment of type 2 diabetes ... Francisco, CA: , (Logo: http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO ) , ... Lowers Plasma Glucose, HbA1c and Reduces Weight in a ...
... , GAITHERSBURG, Md., Nov. 5 GenVec, Inc. (Nasdaq: GNVC ... September 30, 2009. GenVec reported a net loss of $3.6 million ... compared to a net loss of $6.8 million ($0.08 per share) ... September 30, 2009, GenVec,s net loss was $14.1 million ($0.15 per ...
Cached Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6
(Date:7/31/2014)... first-of-its-kind study of bigeye tuna movements in the northwestern ... Large Pelagics Research Center at the University of Massachusetts ... a wide geographical range with pronounced north-south movements from ... a high-use area off Cape Hatteras southwest of Bermuda ... new approach to study one of the most important ...
(Date:7/31/2014)... U.S. Census Bureau, Latinos are the largest minority group ... Approximately one-third of Latinos are obese and are ... non-Hispanic Whites. , NYU College of Nursing student ... to identify the factors that contribute to this problem ... focused on food patterns in Latina women recently published ...
(Date:7/31/2014)... NCT00518336) shows the sustained efficacy, immunogenicity and ... vaccine Cervarix. Women vaccinated with the HPV-16/18 ... nine years, and vaccine efficacy (VE) against ... longest follow-up report for a licensed HPV ... full paper. , HPV and vaccination ...
Breaking Biology News(10 mins):Study of bigeye tuna in Northwest Atlantic uses new tracking methods 2Study of bigeye tuna in Northwest Atlantic uses new tracking methods 3NYU research looks to combat US Latina immigrant obesity 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3
... fever wax and wane over a period of several ... the incidence and range of the potentially deadly mosquito-borne ... has never been more important. , A new study ... a brief period of cross-immunity conferred by any one ...
... led by a conservationist from the Bronx Zoo-based Wildlife ... European Union project CURESS near Chad's Zakouma National Park, ... only their tusks -- a sure sign that poaching ... protected area. , Mike Fay, a WCS conservationist and ...
... genes with a single injection into a vein holds ... heart, University of Florida researchers report. , UF researchers ... with a form of muscular dystrophy that damages the ... monkeys and found genes were readily absorbed by heart ...
Cached Biology News:UGA study explains peaks and troughs of dengue epidemics 2UGA study explains peaks and troughs of dengue epidemics 3Widespread elephant slaughter discovered in Chad 2UF scientists test improved gene therapy method for hereditary heart conditions 2UF scientists test improved gene therapy method for hereditary heart conditions 3UF scientists test improved gene therapy method for hereditary heart conditions 4
LIGHT DIAGNOSTICS Echovirus Blend Reagent, ~50 tests, included in kit #3340 & #3365...
Goat polyclonal to Rabenosyn 5 ( Abpromise for all tested applications). Antigen: Synthetic peptide: ELKHTLAKQKGGTD, corresponding to C terminal amino acids 771-784 of Human Rabenosyn 5. Entr...
TRIAL SIZE Anti-Kaede [2F4] Monoclonal Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Phospho-C/EBPbeta (Thr235) Antibody...
Biology Products: